PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors
Rhea-AI Filing Summary
PDS Biotechnology Corporation reported results of its 2026 annual stockholders meeting held on August 10, 2026. Stockholders approved an amendment to the Eighth Amended and Restated Certificate of Incorporation increasing authorized common stock from 150,000,000 to 300,000,000 shares; the charter is unchanged otherwise.
Two Class B directors, Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified the appointment of KPMG US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Of 55,815,653 shares entitled to vote, 31,594,722 shares (approximately 56.60%) were represented in person or by proxy, constituting a quorum for conducting business.
Positive
- None.
Negative
- None.
Filing Explained
The approved charter amendment raises the authorized common-stock limit, creating additional issuance capacity rather than an immediate change in existing holders’ share count.
8-K Event Classification
3 items: 5.03, 5.07, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Authorized common stock after amendment: 300,000,000 shares
Authorized common stock before amendment: 150,000,000 shares
Shares entitled to vote: 55,815,653 shares
+4 more
7 metrics
Authorized common stock after amendment
300,000,000 shares
Authorized common stock par value $0.00033 per share after charter amendment
Authorized common stock before amendment
150,000,000 shares
Authorized common stock prior to charter amendment
Shares entitled to vote
55,815,653 shares
Common stock entitled to vote at the 2026 annual meeting
Shares represented at meeting
31,594,722 shares
Shares represented in person or by proxy, approximately 56.60% of entitled shares
Meeting participation percentage
56.60%
Portion of shares entitled to vote that were represented, constituting a quorum
Votes for charter amendment
19,904,111 votes
Votes cast in favor of increasing authorized common stock
Votes for auditor ratification
30,351,424 votes
Votes for ratifying KPMG US LLP as independent auditor for 2026
Key Terms
authorized common stock, Eighth Amended and Restated Certificate of Incorporation, broker non-votes, non-binding advisory vote, +1 more
5 terms
authorized common stock financial
"The Amendment increased the number of shares of authorized common stock"
Eighth Amended and Restated Certificate of Incorporation regulatory
"an amendment to the Eighth Amended and Restated Certificate of Incorporation"
broker non-votes financial
"Votes For | | Votes Against | | Votes Abstaining | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory vote regulatory
"A proposal to approve, by non-binding advisory vote, the compensation"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
quorum regulatory
"were represented at the Annual Meeting in person or by proxy, constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
FAQ
What charter change did PDSB stockholders approve at the 2026 annual meeting?
Stockholders approved an amendment increasing authorized common stock from 150,000,000 to 300,000,000 shares. The company states its charter remains unchanged in all other respects following this amendment.
Which directors of PDS Biotechnology (PDSB) were elected in 2026 and for how long?
Stockholders elected Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D. as Class B directors. Each will hold office until the 2029 annual meeting of stockholders or until a successor is duly elected and qualified.
Did PDSB stockholders ratify the appointment of KPMG US LLP for 2026?
Yes. Stockholders ratified KPMG US LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 30,351,424 votes for, 520,018 against, and 723,280 abstaining.
How did PDSB stockholders vote on executive compensation in 2026?
Stockholders approved, by non-binding advisory vote, the compensation of the company’s named executive officers. The vote totals were 7,237,690 for, 3,960,228 against, 1,069,250 abstaining, and 19,327,554 broker non-votes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
